FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
The Inflation Reduction Act (IRA) represents a transformative shift in US health care policy by enabling Medicare to negotiate drug prices for high-expenditure medicatio ...
PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.
The therapy shrunk tumors in 46 percent of patients in a Phase I trial and showed strong PSA responses at the recommended dose.
About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.
Researchers and clinicians from six leading medical centers and academic institutions—including the University of California San Diego—have collaborated to develop a new artificial intelligence model ...
Dr. Ali Kasraeian from Kasraeian Urology is the first in our area to utilize a new minimally invasive treatment, called Focal Therapy, that precisely targets and destroys prostate cancer tumors.
CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.
Incontinence and other urinary problems after prostate cancer treatment can be eased with Kegel exercises, bladder training, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results